JnJ enters innovative rheumatoid arthritis alliance
This article was originally published in Scrip
UK biotech Modern Biosciences (MBS) has entered into an R&D alliance and global option and license agreement with J&J's Janssen Biotech for its novel bone-protective compounds for the treatment of rheumatoid arthritis. Under the deal, facilitated by the Johnson & Johnson Innovation Centre in London, MBS will receive an upfront payment and potential milestones of up to £176m and royalties on any future sales of products arising from the alliance.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.